Dendritic Killer Cell-based Immunotherapy for Solid Tumors
Ontology highlight
ABSTRACT: The primary objective of this study is to evaluate the safety of autologous dendritic killer cell (DKC) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (MTD) of DKC. The primary endpoint of safety evaluation includes physical examination, assessment of vital sign, laboratory test, concomitant medication, and adverse event (AE). The secondary endpoints regarding efficacy includes the generation of tumor specific immune response by detecting CD3+ CD8+ CD69+ IFN-gamma+ T cells, and the improvement of quality of life
DISEASE(S): Neoplasm Metastasis,Colorectal Neoplasms,Neoplasms,Hepatocellular Carcinoma
PROVIDER: 2223614 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA